explore -WSS

explore

author：hotspot 2025-08-23 03:45:19 - browse：484

Humana’s Medicare Advantage enrollees got care in the hospital and physician clinics way more often than the company predicted at the end of 2023, forcing the health insurance giant on Thursday to drastically slash its profit projections for both 2023 and 2024.

Those higher medical costs will wipe away more than $775 million of profit that Humana had expected to bank for 2023. Humana also is “currently assessing the expected impact of emerging utilization trends on its 2024 outlook, which is anticipated to be material if current trends continue,” according to the company’s update to investors.

Humana’s bad news for Wall Street didn’t end there: The company said it appears it only added just 100,000 new Medicare Advantage members from the most recent enrollment period that ended last month — down from estimates that it would enroll anywhere from 325,000 to 435,000 people.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Medicare Advantage proposed rates disappoint insurers

focus

WSS

Startup Neumora takes a novel depression drug to Phase 3

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Medicare Advantage proposed rates disappoint insurers

WHO calls for emergency meeting on new China virus, as cases spread

Cosmetics set for new safety regulation. Why the industry is on board

PhRMA lawsuit over Medicare drug price negotiation tossed

hotspot

explore

focus

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why did Pfizer dish out millions for a Super Bowl ad?

The high cost of giving birth even with insurance

KalVista pill reduced swelling 'attacks' caused by genetic disease

Jerome Adams on the need for new antivirals for Covid

Group opposing PBM reform sets lobbying record

Trump demands the U.S. pay no more for drugs than other countries … again

Biden report: The neurospychology of memory and aging

Tori Bowie and the unacceptable rates of Black maternal death

Vaccine advisory panel ACIP left half staffed by HHS

entertainment

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

Key House Republican on health care plans exit from Congress

BioAge raises $170M for combination therapy with Zepbound

Why hospitals are withdrawing from US News rankings

Industry veterans launch new biotech VC with $310M

leisure time

hotspot

focus

hotspot